Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Semaglutide in Subjects With Type 2 Diabetes and Chronic Kidney Disease
CTR20192594Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by Novo Nordisk. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20192594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192594.